BALA CYNWYD, Pa., July 08, 2024 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( jbrodsky@brodskysmith.com ) or Marc Ackerman ( mackerman@brodskysmith.com ) at 855-576-4847. There is no cost or financial obligation to you.
Morphic Holding, Inc. (Nasdaq - MORF)
Under the terms of the agreement, Morphic will be acquired by Eli Lilly and Company ("Lilly") (NYSE - LLY) for $57.00 per share in cash, an aggregate of $3.2 billion, upon closing of the transaction. The investigation concerns whether the Morphic Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether Lilly is paying fair value to shareholders of the Company. For example, the deal price is below the 52-week high of $62.08 for the Company's shares.
Additional information can be found at https://www.brodskysmith.com/cases/morphic-holding-inc-nasdaq-morf/ .
Desktop Metal, Inc. (NYSE - DM)
Under the terms of the agreement, Desktop Metal will be acquired by Nano Dimension Ltd. ("Nano Dimension") (Nasdaq - NNDM) for $5.50 per share in cash, subject to possible downward adjustments to $4.07 per share. The investigation concerns whether the Desktop Metal Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether Nano Dimension is paying fair value to shareholders of the Company. For example, the deal price is below the 52-week high of $20.00 for the Company's shares.
Additional information can be found at https://www.brodskysmith.com/cases/desktop-metal-inc-nyse-dm/ .
Avangrid, Inc. (NYSE - AGR)
Under the terms of the agreement, Avangrid will be acquired by its majority shareholder, Iberdrola, S.A. ("Iberdrola"). Iberdrola will acquire the remaining 18.4% of the issued and outstanding shares of common stock of Avangrid that it does not currently own for $35.75 per share in an all-cash transaction. The investigation concerns whether the Avangrid Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the deal consideration offers fair value to the Company's minority shareholders.
Additional information can be found at https://www.brodskysmith.com/cases/avangrid-inc-nyse-agr/ .
Alimera Sciences, Inc. (Nasdaq - ALIM)
Under the terms of the agreement, Alimera will be acquired by ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq - ANIP) for $5.50 per share in cash at closing and one non-tradable contingent value right (CVR) representing the right to receive up to $0.50 per share upon the achievement of certain net revenue targets in 2026 and 2027. The investigation concerns whether Alimera Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether ANI is paying fair value to shareholders of the Company. For example, the up-front deal consideration is below the 52-week high of $5.65 for the Company's shares.
Additional information can be found at https://www.brodskysmith.com/cases/alimera-sciences-inc-nasdaq-alim/ .
Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.
Attachments
Disclaimer
Alimera Sciences Inc. published this content on 08 July 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 08 July 2024 14:19:14 UTC.